Trial Profile
A Double-Blind, Placebo-Controlled Dose Escalation Study of the Administration of Multiple Intravenous Doses of RSLV-132 in Subjects With Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2018
Price :
$35
*
At a glance
- Drugs RSLV 132 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Proof of concept
- Sponsors Resolve Therapeutics
- 26 May 2016 Results will be presented at International Rheumatology Conference, as per Resolve Therapeutics media release.
- 10 Feb 2016 Results published in the Resolve Therapeutics Media Release
- 08 Dec 2015 Trial phase changed from II to I, Trial focus changed from TU to AR as reported by ClinicalTrials.gov record.